Paper

Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.

Published Dec 13, 2019 · D. MacKinnon-Cameron, L. Ye, J. Dale

Vaccine

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Rigorous Journal

Study Snapshot

The 30-valent M protein-based streptococcal vaccine was well-tolerated and immunogenic in healthy adults, supporting further clinical development.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.

References

Citations